Table 1 Clinicopathological characteristics of the HER2+ cohort
Characteristic | N° patients | % | Median | Range |
|---|---|---|---|---|
Total number of patients | 86 | |||
Age (years) | 50 | 25–79 | ||
Length follow-up (months) | 30 | 6–112 | ||
Menopausal status | ||||
Pre | 48 | 55.8 | ||
Post | 38 | 44.2 | ||
Tumor size | ||||
T1 | 33 | 38.8 | ||
T2 | 36 | 42.4 | ||
T3 | 12 | 14.1 | ||
T4 | 4 | 4.7 | ||
Not documented | 1 | |||
Lymph node status | ||||
N0 | 44 | 51.2 | ||
N1 | 30 | 34.9 | ||
N2 | 5 | 5.8 | ||
N3 | 7 | 8.1 | ||
Clinical stage | ||||
I | 25 | 29.1 | ||
II | 40 | 46.5 | ||
III | 21 | 24.4 | ||
Histological grade | ||||
1 | 7 | 8.9 | ||
2 | 28 | 35.4 | ||
3 | 44 | 55.7 | ||
Not documented | 7 | |||
Estrogen receptor positive | 66.3 | |||
Progesterone receptor positive | 55.8 | |||